{
  "docId": "019de074-ca9a-70d9-9ba2-1d5f94361fe0",
  "docSlug": "6d754588aa25b32079af055d51113b03",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 38,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "The slide outlines a multi-part clinical trial design with specific dosing cohorts and eligibility requirements.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ca9a-70d9-9ba2-1d5f94361fe0/10",
  "deckHref": "/decks/019de074-ca9a-70d9-9ba2-1d5f94361fe0",
  "deckJsonHref": "/decks/019de074-ca9a-70d9-9ba2-1d5f94361fe0.json",
  "deckAnchorHref": "/decks/019de074-ca9a-70d9-9ba2-1d5f94361fe0#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.325,
        "x": 0.612,
        "y": 0.577
      },
      "kind": "callout",
      "text": "Completed Dosing in Cohort 3",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed3c4168-8fc2-4516-82e3-584829677271",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.475,
        "w": 0.937,
        "x": 0.063,
        "y": 0.225
      },
      "kind": "diagram",
      "text": "PART 1 (Intravenous) to PART 2 (Subcutaneous) flow",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fc66061-dbb0-4be8-929a-985a646ebe56",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.335,
        "w": 0.285,
        "x": 0.348,
        "y": 0.577
      },
      "kind": "list",
      "text": "Key Inclusion Criteria: Classical HCU diagnosis, Plasma homocysteine >=50 uM, >=12 years of age",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b5787b1-f71d-4371-8611-2ff4bcf57400",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.335,
        "w": 0.285,
        "x": 0.065,
        "y": 0.577
      },
      "kind": "list",
      "text": "Endpoints & Design: Safety, Pharmacokinetics, Reduction in plasma homocysteine, 4 once weekly doses",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0146482-f6ec-4f6e-bc13-ee4e9d1f6a4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.091,
        "w": 0.417,
        "x": 0.068,
        "y": 0.045
      },
      "kind": "title",
      "text": "Phase 1/2 Clinical Trial Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56db9c66-4d00-41ca-a2f8-e3d129c0c665",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "SCQA Framework",
      "slug": "scqa-framework",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "e5cdb641-2dc2-4ae7-9ef6-0df0ae9e3bd7",
      "evidence": "Endpoints & Design: Safety, Pharmacokinetics, Reduction in plasma homocysteine, 4 once weekly doses",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "c5460d5e-c6bc-4d6f-b39e-a1acc83e53db",
      "evidence": "Visual representation of cohorts and study parameters",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 11,
      "from": 10,
      "beatId": "b32cfa0c-61fe-428f-a501-3e7c1727ffcf",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slides 10-11 present the Phase 1/2 clinical trial design and interim results for Pegtarviliase",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 38,
      "from": 3,
      "beatId": "e469074b-5500-4414-8b81-ef0652ee8a7d",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 3-38 present various traction metrics, including clinical trial results and financial summaries",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}